Synthesis and antiparasitic and antitumor activity of 2,4-diamino-6- (arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim

Journal of Medicinal Chemistry

Volumn 42, Issue 6, 1999, Pages 1007-1017

  Rosowsky, Andre ^a   Papoulis, Andrew T ^a   Forsch, Ronald A ^a   Queener, Sherry F ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE INHIBITOR; PIRITREXIM; TETRAHYDROQUINAZOLINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; FOLIC ACID ANTAGONISTS; HUMANS; LIVER; LUNG; MICE; PNEUMOCYSTIS; PYRIMIDINES; QUINAZOLINES; RATS; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TUMOR CELLS, CULTURED;

EID: 0033602515     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980572i     Document Type: Article

References (37)

1. Presented in part at the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, June 16-19, 1998; Abstr. 120.
2. (a) Rosowsky, A.; Mota, C. E.; Wright, J. E.; Freisheim, J. H.; Heusner, J. J.; McCormack, J. J.; Queener, S. F. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Med. Chem. 1993, 36, 3103-3112.
3. (b) Rosowsky, A.; Mota, C. E.; Wright, J. E.; Queener, S. F. 2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity. J. Med. Chem. 1994, 37, 4522-4528.
4. (c) Rosowsky, A.; Mota, C. E.; Queener, S. F. Synthesis and antifolate activity of 2,4-diamino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine analogues of trimetrexate and piritrexim. J. Heterocycl. Chem. 1995, 32, 335-340.
5. (d) Rosowsky, A.; Mota, C. E.; Queener, S. F.; Waltham, M.; Ercikan-Abali, E.; Bertino, J. R. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 38, 745-752.
6. (e) Rosowsky, A.; Forsch, R. A.; Queener, S. F. 2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 38, 2615-2620.
7. (f) Rosowsky, A.; Mota, C. E.; Queener, S. F. Brominated trimetrexate analogues as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Heterocycl. Chem. 1996, 33, 1959-1966.
8. (g) Rosowsky, A.; Papoulis, A. T.; Queener, S. F. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Med. Chem. 1997, 40, 3694-3699.
9. (h) Rosowsky, A.; Papoulis, A. T.; Queener, S. F. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Med. Chem. 1998, 41, 913-918.
10. For reviews of the work of other groups in this area, see: (a) Queener, S. F. New drug developments for opportunistic infections in immunocompromised patients: Pneumocystis carinii. J. Med. Chem. 1995, 38, 4739-4759.
11. (b) Gangjee, A.; Elzein, E.; Kothare, M.; Vasudevan, A. Classical and nonclassical antifolates as potential antitumor, antipneumocystis and antitoxoplasma agents. Curr. Pharm. Des. 1996, 2, 263-280.
12. (a) Fischl, M. A.; Dickinson, G. M.; La Voie, L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. J. Am. Med. Assoc. 1988, 259, 1185-1189.
13. (b) Medina, I.; Mills, J.; Leoung, G.; Hopewell, P. C.; Lee, B.; Modin, G.; Benowitz, N.; Wofsy, C. B. Oral therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprimsulfamethoxazole versus trimethoprim-dapsone. N. Engl. J. Med. 1990, 323, 776-782.
14. (c) Sattler, F. R.; Frame, P.; Davis, R.; Nichols, L.; Shelton, B.; Akil, B.; Baughman, N.; Hughlett, C.; Weiss, W.; Boyle, C. T.; van der Horst, C.; Black, J.; Powderly, W.; Steigbigel, R. T.; Leedom, J. M.; Masur, J.; Feinberg, J.; Benoit, S.; Eyster, E.; Gocke, D.; Beck, K.; Lederman, M.; Phari, J.; Reighman, R.; Sacks, H. S.; Soiero, R. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS - - a prospective, controlled multicenter investigation of the AIDS clinical trials group protocol 029/031. J. Infect. Dis. 1994, 770, 165-172.
15. (d) Podzamczer, D.; Salazar, A.; Jimenez, J.; Consiglio, E.; Santin, M.; Casanova, A.; Rufi, G.; Guidol, F. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients with HIV. Ann. Intern. Med. 1995, 122, 755-761.
16. Grivsky, E. M.; Lee, S.; Sigel, C. W.; Duch, D. S.; Nichol, C. A. Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine. J. Med. Chem. 1980, 23, 327-329.
17. (a) Kovacs, J. A.; Allegra, C. J.; Swan, J. C.; Drake, J. C.; Parrillo, J. E.; Chabner, B. A.; Masur, H. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob. Agents Chemother. 1988, 32, 430-433.
18. (b) Falloon, J.; Allegra, C.; Kovacs, J.; O'Neill, D.; Ogata-Arakaki, D.; Feuerstein, I.; Polis, M.; Davey, R.; Lane, H. C.; LaFon, S.; Rogers, M.; Zunich, K.; Turlo, J.; Tuazon, C.; Parenti, D.; Simon, G.; Masur, H. Piritrexim with leucovorin for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Clin. Res. 1990, 38, 361A.
19. (a) Sigel, C. W.; Macklin, A. W.; Woolley, J. L., Jr.; Johnson, N. W.; Collier, M. A.; Blum, M. R.; Clendeninn, N. J.; Everitt, B. J. M.; Grebe, G.; Mackars, A.; Foss, R. G.; Duch, D. S.; Bowers, S. W.; Nichol, C. A. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. NCI Monogr. 1987, 5, 111-120.
20. (b) Laszlo, J.; Brenckman, W. D.; Morgan, E.; Clendeninn, N. J.; Williams, T.; Currie, V.; Young, C. Initial clinical studies of piritrexim. NCI Monogr. 1987, 5, 121-125.
21. Gangjee, A.; Zeveri, N.; Kothare, M.; Queener, S. F. Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities. J. Med. Chem. 1995, 38, 3660-3668.
22. For previous examples of 2,4-diamino-5,6,7,8-tetrahydroquinazolines prepared by this method from substituted cyclohexanones, see: Modest, E. J.; Chatterjee, S.; Protopapa, H. K. 2,4-Diaminopyrimidines from dicyandiamide. III. Reaction with monocyclic ketones. J. Org. Chem. 1965, 30, 1837-1840.
23. Ashby, E. C.; Lin, J. J. Selective reduction of alkenes and alkynes by the reagent lithium aluminum hydride - transition metal halide. J. Org. Chem. 1978, 43, 2567-2572.
24. Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
25. Chio, L.-C.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
26. Rosowsky, A.; Hynes, J. B.; Queener, S. F. Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1995, 39, 79-86.
27. Kovacs, J. A.; Allegra, C. J.; Beaver, J.; Boarman, D.; Lewis, M.; Parrillo, J. E.; Chabner, B.; Masur, H. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: Potential for screening therapeutic agents. J. Infect. Dis. 1989, 160, 312-320.
28. (a) Queener, S. F.; Bartlett, M. S.; Jay, M. A.; Durkin, M. M.; Smith, J. W. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob. Agents Chemother. 1987, 31, 1323-1327.
29. (b) Bartlett, M. S.; Shaw, M.; Navaran, P.; Smith, J. W.; Queener, S. F. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimicrob. Agents Chemother. 1995, 39, 2436-2441.
30. (a) Danemann, B. R.; Israelski, D. M.; Remington, J. S. Treatment of toxoplasmic encephalitis with intravenous clindamycin. Arch. Intern. Med. 1988, 148, 2477-2482.
31. (b) Danemann, B.; McCutchan, J. A.; Israelski, D.; Antoniskis, D.; Leport, C.; Luft, B.; Nussbaum, J.; Clumeck, N.; Morlat, P.; Chiu, J.; Vilde, J. L.; Orellena, M.; Feigal, D.; Bartok, A.; Heseltine, P.; Leedom, J.; Remington, J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann. Intern. Med. 1992, 116, 33-43.
32. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 93, 757-766.
33. Fry, D. W.; Besserer, J. A. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res. 1988, 48, 6986-6991.
34. Patel, M.; Sleep, S. E. H.; Lewis, W. S.; Spencer, H. T.; Mareya, S. M.; Sorrentino, B. P.; Blakley, R. L. Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants. Human Gene Ther. 1997, 8, 2069-2077.
35. Baker, B. R.; Gibson, R. E. Irreversible enzyme inhibitors. 181. Inhibition of brain choline acetyltransferase by derivatives of stilbazole. J. Med. Chem. 1971, 14, 315-322.
36. Baker, B. R.; Gibson, R. E. Irreversible enzyme inhibitors. 193. Inhibition of choline acetyltransferase. Mode of binding by 4-stilbazoles. J. Med. Chem. 1972, 15, 639-642.
37. Jones, R. A.; Talmet, M.-A. The infrared spectra of quaternary 'onium cations of group VB elements. Austral. J. Chem. 1965, 18, 903-906.